ArticleRisk management and healthcare policy2025
Risk Stratification for Cephalosporin-Induced Thrombocytopenia: Development and Validation of a Multidimensional Predictive Model in Older Adults.
Article in Risk management and healthcare policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and Validation of an Interpretable Machine Learning Model for Predicting Thrombocythemia Risk During Third Generation Cephalosporin Therapy.Journal of blood medicine · 2026Article
- Interpretable Machine Learning for Predicting Cefoperazone-Sulbactam-Associated Coagulation Abnormalities in Elderly Inpatients: A Dual-Center Retrospective Study.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Third-generation cephalosporins, while widely prescribed, carry underquantified thrombocytopenia risks in older adults. This study aimed to develop and validate a clinical prediction model for cephalosporin-associated thrombocytopenia in hospitalized patients aged over 65 years. Methods: A retrospective cohort (2019~2023) initially included 45,779 cephalosporin treated patients. After applying exclusion criteria, 12,917 patients were analyzed. Predictors were selected via LASSO regression, with backward elimination multivariate logistic regression constructing a nomogram. Model performance was assessed using AUC, calibration curves, and decision curve analysis (DCA) in training and testing sets. Results: The final model identified eight predictors: baseline platelet count (PLT), red blood cell count (RBC), presence of tumor, renal insufficiency (RI), liver cirrhosis (LC), meropenem use, use of antifungal drugs (AD), and daily usage frequency (DUF). It demonstrated strong discrimination (training AUC 0.82 [95% CI 0.79-0.85]; testing AUC 0.80 [0.76-0.84]) and calibration (Brier score 0.057). DCA confirmed clinical utility across wide risk thresholds. Conclusion: This nomogram tool enables rapid thrombocytopenia risk assessment in elderly patients receiving cephalosporins. Clinically, it guides antibiotic selection by quantifying comorbidity-drug interactions, and improves toxicity monitoring accuracy in complex geriatric cases with polypharmacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.